- Home
- PYXS vs YI Comparison
PYXS vs YI Comparison
Compare PYXS & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYXS
- YI
- Stock Information
- Founded
- PYXS 2018
- YI 2010
- Country
- PYXS United States
- YI China
- Employees
- PYXS N/A
- YI N/A
- Industry
- PYXS Biotechnology: Pharmaceutical Preparations
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- PYXS Health Care
- YI Consumer Staples
- Exchange
- PYXS Nasdaq
- YI Nasdaq
- Market Cap
- PYXS 66.3M
- YI 70.0M
- IPO Year
- PYXS 2021
- YI N/A
- Fundamental
- Price
- PYXS $1.22
- YI $8.14
- Analyst Decision
- PYXS Strong Buy
- YI
- Analyst Count
- PYXS 5
- YI 0
- Target Price
- PYXS $9.00
- YI N/A
- AVG Volume (30 Days)
- PYXS 411.8K
- YI 12.9K
- Earning Date
- PYXS 05-15-2025
- YI 06-10-2025
- Dividend Yield
- PYXS N/A
- YI N/A
- EPS Growth
- PYXS N/A
- YI N/A
- EPS
- PYXS N/A
- YI N/A
- Revenue
- PYXS N/A
- YI $1,973,017,082.00
- Revenue This Year
- PYXS N/A
- YI N/A
- Revenue Next Year
- PYXS N/A
- YI N/A
- P/E Ratio
- PYXS N/A
- YI N/A
- Revenue Growth
- PYXS N/A
- YI N/A
- 52 Week Low
- PYXS $0.83
- YI $4.15
- 52 Week High
- PYXS $5.39
- YI $12.90
- Technical
- Relative Strength Index (RSI)
- PYXS 55.44
- YI 53.37
- Support Level
- PYXS $1.20
- YI $6.91
- Resistance Level
- PYXS $1.20
- YI $8.16
- Average True Range (ATR)
- PYXS 0.08
- YI 0.38
- MACD
- PYXS 0.00
- YI 0.04
- Stochastic Oscillator
- PYXS 80.85
- YI 91.79
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.